Wednesday, June 10, 2026

Patent directory · USPTO A61K / A61P

Patents matching “REGENERON PHARMACEUTICALS, INC.”

837 pharma patents match "REGENERON PHARMACEUTICALS, INC." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 837
Index total 30,257
Page 8 / 35

Quick answer

This filtered view shows 837 pharmaceutical patents matching "REGENERON PHARMACEUTICALS, INC." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

837 results for “REGENERON PHARMACEUTICALS, INC.” · 30,257 patents in full index Clear search

  1. US 11910788

    Mouse having a humanized cluster of differentiation 47 gene

    REGENERON PHARMACEUTICALS, INC. · Granted Feb 27, 2024 · Expires Feb 22, 2044

    granted
  2. US 11910787

    Rodents having a humanized TMPRSS gene

    REGENERON PHARMACEUTICALS, INC. · Granted Feb 27, 2024 · Expires Feb 22, 2044

    granted
  3. US 11912767

    EGFR × CD28 multispecific antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Feb 27, 2024 · Expires Feb 22, 2044

    granted
  4. US 11904017

    Methods for reducing or eliminating the need for lipoprotein apheresis in patients with hyperlipidemia by administering alirocumab

    REGENERON PHARMACEUTICALS, INC. · Granted Feb 20, 2024 · Expires Feb 15, 2044

    granted
  5. US 11905332

    Antigen-binding molecules that bind CD38 and/or CD28, and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Feb 20, 2024 · Expires Feb 15, 2044

    granted
  6. US 11897945

    Methods of treating allergy using anti-Bet v 1 antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Feb 13, 2024 · Expires Feb 8, 2044

    granted
  7. US 11896682

    Radiolabeled MET binding proteins for immuno-PET imaging and methods of use thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Feb 13, 2024 · Expires Feb 8, 2044

    granted
  8. US 11891607

    Methods of treating decreased bone mineral density with cluster of differentiation 109 (CD109) inhibitors

    REGENERON PHARMACEUTICALS, INC. · Granted Feb 6, 2024 · Expires Feb 1, 2044

    granted
  9. US 11884736

    Antibodies which bind to glucagon-like peptide 1 receptor (GLP1R)

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 30, 2024 · Expires Jan 25, 2044

    granted
  10. US 11884707

    Compositions for detection, inhibition and imaging of indoleamine 2, 3-dioxygenase 1 (IDO1) and methods of making and using same

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 30, 2024 · Expires Jan 25, 2044

    granted
  11. US 11866502

    Anti-FGFR2 antibodies and methods of use thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 9, 2024 · Expires Jan 4, 2044

    granted
  12. US 11866503

    Methods for treating inflammatory conditions of the airway or lungs by administering antagonist monoclonal antibodies to interleukin-33 and interleukin-4 receptor

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 9, 2024 · Expires Jan 4, 2044

    granted
  13. US 11866794

    Cas-ready mouse embryonic stem cells and mice and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 9, 2024 · Expires Jan 4, 2044

    granted
  14. US 11865134

    Treatment of inflammation with glucocorticoids and angiopoietin-like 7 (ANGPTL7) inhibitors

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 9, 2024 · Expires Jan 4, 2044

    granted
  15. US 11850535

    Methods for quantitating individual antibodies from a mixture

    REGENERON PHARMACEUTICALS, INC. · Granted Dec 26, 2023 · Expires Dec 21, 2043

    granted
  16. US 11844765

    Treatment of inflammatory conditions by delivery of interleukin-1 receptor antagonist fusion protein

    REGENERON PHARMACEUTICALS, INC. · Granted Dec 19, 2023 · Expires Dec 14, 2043

    granted
  17. US 11845963

    HSD17B13 variants and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Dec 19, 2023 · Expires Dec 14, 2043

    granted
  18. US 11845800

    Methods for treating or preventing asthma by administering an IL-4R antagonist

    REGENERON PHARMACEUTICALS, INC. · Granted Dec 19, 2023 · Expires Dec 14, 2043

    granted
  19. US 11845989

    Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors

    REGENERON PHARMACEUTICALS, INC. · Granted Dec 19, 2023 · Expires Dec 14, 2043

    granted
  20. US 11845931

    CRISPR/Cas screening platform to identify genetic modifiers of tau seeding or aggregation

    REGENERON PHARMACEUTICALS, INC. · Granted Dec 19, 2023 · Expires Dec 14, 2043

    granted
  21. US 11845957

    Models of tauopathy

    REGENERON PHARMACEUTICALS, INC. · Granted Dec 19, 2023 · Expires Dec 14, 2043

    granted
  22. US 11834500

    Bispecific antigen binding molecules that bind leptin receptor and/or GP130, and methods of use thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Dec 5, 2023 · Expires Nov 30, 2043

    granted
  23. US 11834485

    IL-2 variants with reduced binding to IL-2 receptor alpha and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Dec 5, 2023 · Expires Nov 30, 2043

    granted
  24. US 11825819

    Crnn loss of function rodent model

    REGENERON PHARMACEUTICALS, INC. · Granted Nov 28, 2023 · Expires Nov 23, 2043

    granted